NRC Q4 revenue $36.9M, EPS $0.28; CTO Louvion resigns

NRC HEALTH

2024-FY EPS reported $1.04 revenue$143,060,000

Q4 revenue $36.9M vs $38.0M YoY; diluted EPS $0.28 vs $0.36.
Net indebtedness $58.5M; total recurring contract value $133.2M at Dec 31, 2024.
Returned $10.1M to shareholders: $7.3M in stock repurchases (393k shares) plus $0.12/share dividend.
Chief Product Technology Officer Chrisophe Louvion resigned effective Jan 27, 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.